Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L. Leslie
Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
The Tempest-A Practical Framework for Network Programmability
IEEE Network
Information Systems
Computer Networks
Hardware
Communications
Architecture
Software
Related publications
PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B-Cell LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Polatuzumab Vedotin (Pola) + Obinutuzumab (G) + Lenalidomide (Len) in Patients (Pts) With Relapsed/Refractory (R/R) Follicular Lymphoma (Fl): Phase Ib/Ii Interim Analysis
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma
American Journal of Hematology
Hematology
Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
British Journal of Haematology
Hematology
The Immunologic Doublet of Lenalidomide Plus Obinutuzumab Is Highly Active in Relapsed/Refractory Follicular Lymphoma, Results of a Phase I/Ii Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Results From the Safety Run-In Period of the Sympatico Study Evaluating Ibrutinib in Combination With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
